2020
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study
Wesolowski R, Stover D, Lustberg M, Shoben A, Zhao M, Mrozek E, Layman R, Macrae E, Duan W, Zhang J, Hall N, Wright C, Gillespie S, Berger M, Chalmers J, Carey A, Balasubramanian P, Miller B, Amaya P, Andreopoulou E, Sparano J, Shapiro C, Villalona‐Calero M, Geyer S, Chen A, Grever M, Knopp M, Ramaswamy B. Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study. The Oncologist 2020, 25: e1158-e1169. PMID: 32452601, PMCID: PMC7418347, DOI: 10.1634/theoncologist.2020-0039.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerHuman epidermal growth receptor 2Advanced breast cancerPhase I studyFLT-PETBreast cancerFood and Drug AdministrationEscalating dosesPartial responseSafety profileArea under the curve 5High dosesEscalating doses of veliparibMaximum standardized uptake valueMedian progression-free survivalHormone receptor (HR)-positiveFanconi anemiaFLT-PET scansPhase II doseRP2D of veliparibDose-limiting toxicityProgression-free survivalEarly response assessmentStandardized uptake valueMonitoring therapy response
2009
Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC)
Gadgeel S, Wozniak A, Edelman M, Valdivieso M, Heilbrun L, Venkatramanamoorthy R, Shields A, LoRusso P, Hackstock D, Ruckdeschel J. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2009, 27: e19007-e19007. DOI: 10.1200/jco.2009.27.15_suppl.e19007.Peer-Reviewed Original ResearchNon-small cell lung cancerRecurrent non-small cell lung cancerFLT-PET scansNSCLC ptsDose reductionPET scansMeasurable non-small cell lung cancerConfirmed response rateDisease control ratePhase II trialMedian age 60Cell lung cancerStandard uptake valueVEGF receptor 1Males 56Pemetrexed combinationsPrior regimensBrain metastasesGrade 3/4II trialVEGF therapyMajor hemorrhageOral inhibitorControl rateLung cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply